clinical trial · NCT06522737
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
SecuraBio·phase3·recruiting·n = 124
LymphomaDuvelisibGemcitabineBendamustine
brief summary
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
started
May 19, 2025
primary completion
Feb 1, 2028
completion
Dec 1, 2028
last updated
Apr 6, 2026
official title
A Multicentre, Open-label, Phase 3, Randomised Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol